Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.
Bibliographical noteFunding Information:
This work was supported by Public Health Service grants CA89652, CA74285, and Cancer Center Support Grant P30 CA77398.
- Insulin-like growth factor receptors
- Insulin-like growth factors
- Monoclonal antibodies
- Tyrosine kinase inhibitors